Agency scientists at the F.D.A. are advising against allowing widespread use of several peptide injections, citing safety concerns and insufficient evidence for broad approval. The internal guidance reflects a cautious regulatory stance grounded in clinical data review.

Meanwhile, Robert F. Kennedy Jr., the newly confirmed health secretary, has publicly stated that people should be free to experiment with such treatments, framing access as a matter of personal choice and medical freedom. This divergence sets up a potential policy clash between career agency scientists and political leadership over the future of peptide regulation.

The peptides in question, often marketed for anti-aging, muscle growth, and metabolic health, have gained popularity through online clinics and wellness influencers despite limited F.D.A. authorization. Kennedy's rhetoric aligns with a broader skepticism of pharmaceutical gatekeeping, but critics warn that loosening restrictions could expose patients to unproven or harmful products. The tension underscores a deeper debate about the balance between innovation, patient autonomy, and evidence-based oversight in American healthcare.